The Pleasant Prairie facility, which spans more than 84,000 square feet, is equipped with state-of-the-art isolator technology and adheres to the highest current good manufacturing practice standards.
The facility will produce a range of injectable medications, providing hospitals and clinicians access to safe, affordable, and critical-need medications.
The rigorous FDA approval process ensures that facilities meet strict safety and quality standards. Nexus Pharmaceuticals, Inc. plans to manufacture a number of NDAs and ANDAs from the Wisconsin-based facility to bring innovative products as well as supply chain durability to the US healthcare system.
The leadership, regulatory, and business functions will remain in the Illinois headquarters facility.
Nexus Pharmaceuticals, Inc., a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice.
Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they're needed most. For more information about Nexus Pharmaceuticals and its manufacturing facility in Wisconsin.
Sandoz to invest USD90m in Biosimilar Technical Development Center in Slovenia
Brenzavvy Now Available for the Treatment of Adults with Type 2 Diabetes
Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Dr. Reddy's rituximab biosimilar candidate undergoes regulatory review in the US, EU and UK
Grossman Named President and Chief Medical Officer at Coya Therapeutics
Endo International launches first generic version of Merck's Noxafil
Global Pharmaceutical CDMO Market to Reach USD 232.587 bn by 2030, According to Research and Markets
Amneal Releases 2022 Environmental, Social and Governance Report
Oliva Therapeutics Forges Long-Term Partnership with Rio Biopharmaceuticals